Experimental Hepatocarcinogenesis

Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms

Volumn , Issue , 2014, Pages 1866-1880

  CavigLia, J M ^a   Schwabe, R F ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cancer stem cell; Carcinogenesis; Fibrosis; Hepatitis; Hepatocellular adenoma; Hepatocellular carcinoma; Humanized mice; Steatosis; Transgenic mice; Tumor microenvironment

Indexed keywords

EID: 84940092433     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-386456-7.04212-X     Document Type: Chapter

References (120)

1. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365(12):1118-1127.
2. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012, 379(9822):1245-1255.
3. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
4. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127(12):2893-2917.
5. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology 2010, 78(Suppl. 1):7-10.
6. De Minicis S., Kisseleva T., Francis H., Baroni G.S., Benedetti A., Brenner D., et al. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig. Liver Dis. 2012, pii:S1590-8658(12)00406-9. 10.1016/j.dld.2012.10.008.
7. Fausto N., Campbell J.S. Mouse models of hepatocellular carcinoma. Semin. Liver Dis. 2010, 30(1):87-98. 10.1055/s-0030-1247135.
8. Feo F., Pascale R., Calvisi D. Models for Liver cancer. The Cancer Handbook 2007, 1-16. Wiley, London. M. Alison (Ed.).
9. Heindryckx F., Colle I., Van VLierberghe H. Experimental mouse models for hepatocellular carcinoma research. Int. J. Exp. Pathol. 2009, 90(4):367-386.
10. Leenders M.W., Nijkamp M.W., Borel Rinkes I.H. Mouse models in Liver cancer research: a review of current Literature. World J. Gastroenterol. 2008, 14(45):6915-6923.
11. Newell P., Villanueva A., Friedman S.L., Koike K., Llovet J.M. Experimental models of hepatocellular carcinoma. J. Hepatol. 2008, 48(5):858-879.
12. Fujimoto A., Totoki Y., Abe T., Boroevich K.A., Hosoda F., Nguyen H.H., et al. Whole-genome sequencing of Liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 2012, 44(7):760-764.
13. Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I.B., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 2012, 44(6):694-698.
14. Lee J.S., Chu I.S., Mikaelyan A., Calvisi D.F., Heo J., Reddy J.K., et al. AppLication of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet. 2004, 36(12):1306-1311.
15. Villanueva A., Newell P., Chiang D.Y., Friedman S.L., Llovet J.M. Genomics and signaLing pathways in hepatocellular carcinoma. Semin. Liver Dis. 2007, 27(1):55-76. Review.
16. Wu S.D., Ma Y.S., Fang Y., Liu L.L., Fu D., Shen X.Z. Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat. Rev. 2012, 38(3):218-225.
17. Yang J.D., Nakamura I., Roberts L.R. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin. Cancer Biol. 2011, 21(1):35-43.
18. Burke Z.D., Tosh D. Ontogenesis of hepatic and pancreatic stem cells. Stem Cell Rev. 2012, 8(2):586-596.
19. Friedman J.R., Kaestner K.H. On the origin of the Liver. J. CLin. Invest. 2011, 121(12):4630-4633.
20. Mishra L., Banker T., Murray J., Byers S., Thenappan A., He A.R., et al. Liver stem cells and hepatocellular carcinoma. Hepatology 2009, 49(1):318-329.
21. Rountree C.B., Mishra L., Willenbring H. Stem cells in Liver diseases and cancer: recent advances on the path to new therapies. Hepatology 2012, 55(1):298-306.
22. Turner R., Lozoya O., Wang Y., Cardinale V., Gaudio E., Alpini G., et al. Human hepatic stem cell and maturational Liver Lineage biology. Hepatology 2011, 53(3):1035-1045.
23. Zaret K.S., Grompe M. Generation and regeneration of cells of the Liver and pancreas. Science 2008, 322(5907):1490-1494.
24. Clevers H. The cancer stem cell: premises, promises and challenges. Nat. Med. 2011, 17(3):313-319.
25. Dragani T.A., Manenti G., Gariboldi M., De Gregorio L., Pierotti M.A. Genetics of Liver tumor susceptibiLity in mice. Toxicol. Lett. 1995, 82-83:613-619.
26. Feo F., De MigLio M.R., Simile M.M., Muroni M.R., Calvisi D.F., Frau M., et al. Hepatocellular carcinoma as a complex polygenic disease. Interpretative analysis of recent developments on genetic predisposition. BBA Cancer Rev. 2006, 1765:126-147.
27. Beer S., Zetterberg A., Ihrie R.A., McTaggart R.A., Yang Q., Bradon N., et al. Developmental contextdetermines latency of MYC-induced tumorigenesis. PloS Biol. 2004, 2(11):e332.
28. Shachaf C.M., Kopelman A.M., Arvanitis C., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431:1112-1117.
29. Thorgeirsson S.S., SantoniRugiu E. Transgenic mouse models in carcinogenesis: interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis. Br. J. CLin. Pharmacol. 1996, 42:43-52.
30. Awuah P.K., Rhieu B.H., Singh S., Misse A., Monga S.P. β-catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbitaladministration to mice. PloS One 2012, 7(6):e39771.
31. AydinLik H., Nguyen T.D., Moennikes O., Buchmann A., Schwarz M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse Liver tumors. Oncogene 2001, 20(53):7812-7816.
32. Cadoret A., Ovejero C., Saadi-Kheddouci S., Souil E., Fabre M., Romagnolo B., et al. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res. 2001, 61(8):3245-3249.
33. Colnot S., Decaens T., Niwa-Kawakita M., Godard C., Hamard G., Kahn A., et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaLing and leads to hepatocellular carcinomas. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(49):17216-17221.
34. Harada N., Oshima H., Katoh M., Tamai Y., Oshima M., Taketo M.M. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res. 2004, 64(1):48-54.
35. Nejak-Bowen K.N., Thompson M.D., Singh S., Bowen W.C., Dar M.J., Khillan J., et al. Accelerated Liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology 2010, 51(5):1603-1613.
36. Rignall B., Braeuning A., Buchmann A., Schwarz M. Tumor formation in Liver of conditional β-catenin-deficient mice exposed to adiethylnitrosamine/phenobarbital tumor promotion regimen. Carcinogenesis 2011, 32(1):52-57.
37. Tan X., Apte U., Micsenyi A., Kotsagrelos E., Luo J.H., Ranganathan S., et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in Liver. Gastroenterology 2005, 129(1):285-302.
38. Zhang X.F., Tan X., Zeng G., Misse A., Singh S., Kim Y., et al. Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis:role of oxidative stress and platelet-derived growth factor receptoralpha/phosphoinositide 3-kinase signaLing. Hepatology 2010, 52(3):954-965.
39. Ho C., Wang C., Mattu S., Destefanis G., Ladu S., Delogu S., et al. AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse Liver promotes rapid carcinogenesis by way of mTOR (mammaLian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Hepatology 2012, 55(3):833-845.
40. Sandgren E.P., Quaife C.J., Pinkert C.A., Palmiter R.D., Brinster R.L. Oncogene-induced Liver neoplasia in transgenic mice. Oncogene 1989, 4:715-724.
41. Jacks T., Remington L., WilLiams B.O., Schmitt E.M., Halachmi S., Bronson R.T., et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4(1):1-7.
42. Katz S.F., Lechel A., Obenauf A.C., Begus-Nahrmann Y., Kraus J.M., Hoffmann E.M., et al. Disruption of Trp53 in Livers of mice induces formation of carcinomas with biLineal differentiation. Gastroenterology 2012, 142(5):1229-1239.e3.
43. Morris S.M., Baek J.Y., Koszarek A., Kanngurn S., Knoblaugh S.E., Grady W.M. Transforming growth factor-beta signaLing promotes hepatocarcinogenesis induced by p53 loss. Hepatology 2012, 55(1):121-131.
44. Woo H.G., Wang X.W., Budhu A., et al. Association of TP53 mutations with stem cell-Like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology 2011, 140:1063-1070.
45. Horie Y., Suzuki A., Kataoka E., Sasaki T., Hamada K., Sasaki J., et al. Hepatocyte-specific pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. CLin. Invest. 2004, 113:1774-1783.
46. Watanabe, S., Horie, Y., Kataoka, E., Sato, W., Dohmen, T., Ohshima, S., et al., 2007. Non-alcohoLic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN). J Gastroenterol Hepatol. 22, S96-S100.
47. Jhappan C., Stahle C., Harkins R.N., Fausto N., Smith G.H., MerLino G.T. TGF alpha overexpression in transgenic mice induces Liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990, 61(6):1137-1146.
48. Schnur J., Nagy P., Sebestyen A., Schaff Z., Thorgeirsson S.S. Chemical hepatocarcinogenesis in transgenic mice overexpressing mature TGF beta-1 in Liver. Eur. J. Cancer 1999, 35:1842-1845.
49. Campbell J.S., Hughes S.D., Gilbertson D.G., et al. Platelet derived growth factor C induces Liver fibrosis, steatosis, and hepatocellular carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(9):3389-3394.
50. Apte U., Zeng G., Muller P., Tan X., Micsenyi A., Cieply B., et al. Activation of Wnt/beta-catenin pathway during hepatocyte growthfactor-induced hepatomegaly in mice. Hepatology 2006, 44(4):992-1002.
51. Michalopoulos G.K., DeFrances M.C. Liver regeneration. Science 1997, 276:60-66.
52. Sakata H., Takayama H., Sharp R., Rubin J.S., MerLino G., LaRochelle W.J. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse Livers. Cell Growth Differ. 1996, 7:1513-1523.
53. Shiota G., Wang T.C., Nakamura T., Schmidt E.V. Hepatocyte growth factor in transgenic mice: effects on hepatocyte growth, Liver regeneration and gene expression. Hepatology 1994, 19:962-972.
54. Wang R., Ferrell L.D., Faouzi S., Maher J.J., Bishop J.M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 2001, 153:1023-1034.
55. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21(4):504-516.
56. ElLis J.M., Paul D.S., Depetrillo M.A., Singh B.P., Malarkey D.E., Coleman R.A. Mice deficient in glycerol-3-phosphate acyltransferase-1 have a reduced susceptibiLity to Liver cancer. Toxicol. Pathol. 2012, 40(3):513-521.
57. Solt D.B., Cayama E., Tsuda H., Enomoto K., Lee G., Farber E. Promotion of Liver cancer development by brief exposure to dietary 2-acetylaminofluorene plus partial hepatectomy or carbon tetrachloride. Cancer Res. 1983, 43(1):188-191.
58. Tokumo K., Iatropoulos M.J., WilLiams G.M. Butylated hydroxytoluene lacks the activity of phenobarbital in enhancing diethylnitrosamine-induced mouse Liver carcinogenesis. Cancer Lett. 1991, 59(3):193-199.
59. Verna L., Whysner J., WilLiams G.M. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol. Ther. 1996, 71(1-2):57-81.
60. VesseLinovitch S.D., Mihailovich N. Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res. 1983, 43:4253-4259.
61. VesseLinovitch S.D., Koka M., Mihailovich N., Rao K.V. Carcinogenicity of diethylnitrosamine in newborn, infant, and adult mice. J. Cancer Res. CLin. Oncol. 1984, 108:60-65.
62. McGlynn K.A., Hunter K., LeVoyer T., et al. SusceptibiLity to aflatoxin B-1-related primary hepatocellular carcinoma in mice and humans. Cancer Res. 2003, 63:4594-4601.
63. VesseLinovitch S.D., Mihailovich N., Wogan G.N., Lombard L.S., Rao K.V. Aflatoxin B1, a hepatocarcinogen in the infant mouse. Cancer Res. 1972, 32:2289-2291.
64. Katzenellenbogen M., Mizrahi L., Pappo O., Klopstock N., Olam D., Jacob-Hirsch J., et al. Molecular mechanisms of Liver carcinogenesis in the mdr2-knockout mice. Mol. Cancer Res. 2007, 5(11):1159-1170.
65. Mauad T.H., van Nieuwkerk C.M., Dingemans K.P., Smit J.J., Schinkel A.H., Notenboom R.G., et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 1994, 145(5):1237-1245.
66. Inokuchi S., Aoyama T., Miura K., Osterreicher C.H., Kodama Y., Miyai K., et al. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(2):844-849.
67. Bettermann K., Vucur M., Haybaeck J., Koppe C., Janssen J., Heymann F., et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to Liver cancer. Cancer Cell 2010, 17(5):481-496.
68. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., et al. Deletion of NEMO/IKKgamma in Liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11:119-132.
69. Nikolaou K., Tsagaratou A., Eftychi C., KolLias G., Mosialos G., TaLianidis I. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 2012, 21(6):738-750.
70. Hikita H., Kodama T., Shimizu S., Li W., Shigekawa M., Tanaka S., et al. Bak deficiency inhibits Liver carcinogenesis: a causal Link between apoptosis and carcinogenesis. J. Hepatol. 2012, 57(1):92-100.
71. Weber A., Boger R., Vick B., Urbanik T., Haybaeck J., Zoller S., et al. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proLiferation and hepatocarcinogenesis in mice. Hepatology 2010, 51(4):1226-1236.
72. Hikita H., Kodama T., Shimizu S., Li W., Shigekawa M., Tanaka S., et al. Bak deficiency inhibits Liver carcinogenesis: a causal Link between apoptosis and carcinogenesis. J. Hepatol. 2012, 57(1):92-100.
73. Chisari F.V., Klopchin K., Moriyama T., PasquinelLi C., Dunsford H.A., Sell S., et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989, 59:1145-1156.
74. Kim C.M., Koike K., Saito I., et al. HBx gene of hepatitis B virus induces Liver cancer in transgenic mice. Nature 1991, 353:317-320.
75. Calvisi D.F., Wang C., Ho C., Ladu S., Lee S.A., Mattu S., et al. Increased Lipogenesis, induced by AKT-mTORC1-RPS6 signaLing, promotes development of human hepatocellular carcinoma. Gastroenterology 2011, 140(3):1071-1083.
76. Menon S., Yecies J.L., Zhang H.H., Howell J.J., Nicholatos J., Harputlugil E., et al. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci. Signal. 2012, 5(217):ra24.
77. Villanueva A., Chiang D.Y., Newell P., Peix J., Thung S., Alsinet C., et al. Pivotal role of mTOR signaLing in hepatocellular carcinoma. Gastroenterology 2008, 135(6):1972-1983.
78. Kamegaya Y., et al. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology 2005, 41:660-667.
79. Koike K., et al. Expression of hepatitis C virus envelope proteins in transgenic mice. J. Gen. Virol. 1995, 76(Pt 12):3031-3038.
80. Koike K., Moriya K., Matsuura Y. Animal models for hepatitis C and related Liver disease. Hepatol. Res. 2010, 40(1):69-82.
81. Lerat H., Honda M., Beard M.R., Loesch K., Sun J., Yang Y., et al. Steatosis and Liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002, 122(2):352-365.
82. Li Y., Tang Z.Y., Hou J.X. Hepatocellular carcinoma: insight from animal models. Nat. Rev. Gastroenterol. Hepatol. 2011, 9(1):32-43.
83. Majumder M., et al. Expression of hepatitis C virus non-structural 5A protein in the Liver of transgenic mice. FEBS Lett. 2003, 555:528-532.
84. Moriya K., Fujie H., Shintani Y., Yotsuyanagi H., Tsutsumi T., Ishibashi K., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic., mice. Nat. Med. 1998, 4(9):1065-1067.
85. Akhurst B., Croager E.J., Farley-Roche C.A., Ong J.K., Dumble M.L., Knight B., et al. A modified choLine-deficient, ethionine-supplemented diet protocol effectively induces oval cells in mouse Liver. Hepatology 2001, 34(3):519-522.
86. Ghoshal A.K., Farber E. The induction of Liver cancer by dietary deficiency of choLine and methionine without added carcinogens. Carcinogenesis 1984, 5(10):1367-1370.
87. Knight B., Yeoh G.C., Husk K.L., et al. Impaired preneoplastic changes and Liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med. 2000, 192:1809-1818.
88. Rushmore T.H., Ghazarian D.M., Subrahmanyan V., Farber E., Ghoshal A.K. Probable free radical effects on rat Liver nuclei during early hepatocarcinogenesis with a choLine-devoid low methionine diet. Cancer Res. 1987, 47:6731-6740.
89. Shinozuka H., Lombardi B., Sell S., Iammarino R.M. Early histological and functional alterations of ethionine Liver carcinogenesis in rats fed a choLine-deficient diet. Cancer Res. 1978, 38:1092-1098.
90. Shinozuka H., Lombardi B., Sell S., Iammarino R.M. Enhancement of DL-ethionine-induced Liver carcinogenesis in rats fed a choLine-devoid diet. J. Natl. Cancer Inst. 1978, 61(3):813-817.
91. Fan C.Y., et al. Steatohepatitis, spontaneous peroxisome proLiferation and Liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. ImpLications for peroxisome proLiferator-activated receptor alpha natural Ligand metaboLism. J. Biol. Chem. 1998, 273:15639-15645.
92. Hill-Baskin A.E., Markiewski M.M., Buchner D.A., Shao H., DeSantis D., Hsiao G., et al. Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum. Mol. Genet. 2009, 18(16):2975-2988.
93. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., et al. Dietary and genetic obesity promote Liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140(2):197-208.
94. Machida K., Tsukamoto H., Mkrtchyan H., Duan L., Dynnyk A., Liu H.M., et al. Toll-Like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker nanog. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(5):1548-1553.
95. Machida K., Chen C.L., Liu J.C., Kashiwabara C., Feldman D., French S.W., et al. Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus. J. Gastroenterol. Hepatol. 2012, 27(Suppl. 2):19-22.
96. Inami Y., Waguri S., Sakamoto A., et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J. Cell Biol. 2011, 193:275-284.
97. Takamura A., Komatsu M., Hara T., et al. Autophagy-deficient mice develop multiple Liver tumors. Genes Dev. 2011, 25:795-800.
98. Thomas H.E., Mercer C.A., CarnevalLi L.S., Park J., Andersen J.B., Conner E.A., et al. MTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci. Transl. Med. 2012, 4(139):139ra84.
99. Abushahba W., Balan M., Castaneda I., Yuan Y., Reuhl K., Raveche E., et al. Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol. Immunother. 2010, 59(7):1059-1071.
100. Huynh H., Soo K.C., Chow P.K., Panasci L., Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. CLin. Cancer Res. 2006, 12:4306-4314.
101. Kashofer K., Tschernatsch M.M., Mischinger H.J., Iberer F., Zatloukal K. The disease relevance of human hepatocellular xenograft models: molecular characterization and review of the Literature. Cancer Lett. 2009, 286(1):121. 10.1016/j.canlet.2008.11.011.
102. Kornek M., Raskopf E., Tolba R., Becker U., Klockner M., Sauerbruch T., et al. Accelerated orthotopic HCC growth is Linked to increased expression of pro-angiogenic and pro-metastatic factors in murine Liver fibrosis. Liver Int. 2008, 28:509-518.
103. Tang T.C., Man S., Xu P., et al. Development of a resistance-Like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 2010, 12:928-940.
104. Li Z., Huang X., Zhan H., Zeng Z., Li C., Spitsbergen J.M., et al. Inducible and repressable oncogene-addicted hepatocellular carcinoma inTet-on xmrk transgenic zebrafish. J. Hepatol. 2012, 56(2):419-425.
105. Li Z., Zheng W., Wang Z., Zeng Z., Zhan H., Li C., et al. A transgenic zebrafish Liver tumor model with inducible Myc expressionreveals conserved Myc signatures with mammaLian Liver tumors. Dis. Model. Mech. 2013, 6(2):414-423.
106. Lu J.W., Yang W.Y., Lin Y.M., Jin S.L., Yuh C.H. Hepatitis B virus X antigen andaflatoxin B1 synergistically cause hepatitis, steatosis and Liver hyperplasia in transgenic zebrafish. Acta Histochem. 2013, pii:S0065-1281(13)00048-2. 10.1016/j.acthis.2013.02.012.
107. Mizgireuv I.V., Revskoy S.Y. Transplantable tumor Lines generated in clonalzebrafish. Cancer Res. 2006, 66(6):3120-3125.
108. Mizgireuv I.V., Majorova I.G., Gorodinskaya V.M., Khudoley V.V., Revskoy S.Y. Carcinogenic effect of N-nitrosodimethylamine on diploid and triploid zebrafish (Danio rerio). Toxicol. Pathol. 2004, 32(5):514-518.
109. Mizgirev I., Revskoy S. Generation of clonal zebrafish Lines and transplantablehepatic tumors. Nat. Protoc. 2010, 5(3):383-394.
110. Nguyen A.T., Emelyanov A., Koh C.H., Spitsbergen J.M., Lam S.H., Mathavan S., et al. A high level of Liver-specific expression of oncogenic kras(V12) drivesrobust Liver tumorigenesis in transgenic zebrafish. Dis. Model. Mech. 2011, 4(6):801-813.
111. Nguyen A.T., Emelyanov A., Koh C.H., Spitsbergen J.M., Parinov S., Gong Z. Aninducible kras(V12) transgenic zebrafish model for Liver tumorigenesis and chemical drug screening. Dis. Model. Mech. 2012, 5(1):63-72.
112. Rekha R.D., AmaLi A.A., Her G.M., Yeh Y.H., Gong H.Y., Hu S.Y., et al. Thioacetamide accelerates steatohepatitis, cirrhosis and HCC by expressing HCVcore protein in transgenic zebrafish danio rerio. Toxicology 2008, 243(1-2):11-22.
113. Kang T.W., Yevsa T., Woller N., Hoenicke L., Wuestefeld T., Dauch D., et al. Senescence surveillance of pre-maLignant hepatocytes Limits Liver cancer development. Nature 2011, 479(7374):547-551.
114. American Association for the Study of Liver Diseases (AASLD). http://www.aasld.org.
115. American Liver Foundation (ALF). http://www.Liverfoundation.org/.
116. European Association for the Study of the Liver (EASL). http://www.easl.eu/.
117. International Liver Cancer Association (ILCA). http://www.ilca-onLine.org/.
118. National Cancer Institute's information on Liver cancer - Liver Cancer Home Page. http://www.cancer.gov.
119. National Institute of Diabetes and Digestive and Kidney Diseases's information on Liver cancer. http://www2.niddk.nih.gov.
120. Zebrafish information. http://zfin.org/.